Nature Communications paper on lung cancer niches

Bina Desai and colleagues at Moffitt Cancer Center and Memorial Sloan Kettering Cancer Center reported on May 29 in *Nature Communications* that lung tumors can survive targeted therapy by sheltering in “peristromal niches” — pockets next to tumor-supporting stroma that blunt drug response. The study focused on ALK-positive non-small cell lung cancer models treated with alectinib, a frontline ALK inhibitor, and found that residual cancer cells near stroma were less affected than cells farther away. The authors said the protective effect was not driven by one escape route. Instead, multiple signals from the tumor microenvironment combined to preserve cancer cells during remission and relapse. The paper adds to a broader effort at Moffitt to map how stromal ecology shapes treatment response in lung cancer. A Moffitt project description says targeted therapies against mutant receptor tyrosine kinases such as ALK and EGFR can produce durable responses in advanced non-small cell lung cancer, but some cells persist within minimal residual disease and later seed resistance. ### What is a peristromal niche in this study? (nature.com) The Nature paper defines the key geography as tumor cells positioned close to stromal cells, especially fibroblast-rich regions. In those locations, the authors found cancer cells received local protection during targeted therapy, allowing some cells to persist even when the drug suppressed the main oncogenic driver. The authors said this matters because resistance is often framed as a cell-intrinsic problem — mutations or adaptive programs inside the cancer cell itself. (csbc.moffitt.org) Their data instead tied part of the response to where a cell sits inside the tumor and what neighboring stromal elements provide. ### Which lung cancer setting did the researchers test? The experiments centered on ALK-positive non-small cell lung cancer and responses to alectinib. (nature.com) The bioRxiv version of the work, which matches the final paper’s core framing, said the team assessed stromal resistance in xenograft models and found stroma-proximal tumor cells were partially protected from alectinib’s cytostatic effects. Moffitt separately reported in January that fibroblasts can help ALK-driven lung cancer cells survive targeted treatment through two broad routes: soluble growth-promoting factors and physical adhesion-based support. (nature.com) That earlier institutional summary described the same practical problem — blocking one pathway was not enough to fully remove fibroblast-mediated protection. (pmc.ncbi.nlm.nih.gov) ### What did the paper say about why single-pathway fixes fall short? The Nature Communications article said the sheltering effect reflected “multifactorial” protection. Search summaries of the paper and preprint both describe a combined action of multiple molecular mediators, including growth factors and extracellular matrix components. Because those mechanisms overlap, suppressing any individual one improved response but did not fully erase stromal protection. (moffitt.org) That conclusion matches the Moffitt January release, which said advanced proteomics helped distinguish survival signals coming from cancer cells versus surrounding fibroblasts. The release said those data could inform combination therapies for patients with ALK-driven lung cancer and potentially other tumor types. ### How does this connect to relapse? (nature.com) The paper’s summary says peristromal niches drive persistence and eventual relapse of residual tumors “in tandem with cancer cell-intrinsic resistance mechanisms.” That wording places the microenvironment alongside, rather than instead of, tumor-cell evolution. An AACR abstract from the same research program reported that peristromal niches can mediate a positive ecological interaction between therapy-sensitive and therapy-resistant cells, altering relapse dynamics in lung cancer models. (moffitt.org) That conference abstract is not the new paper, but it shows the group has been developing the same framework across experimental and modeling work. (nature.com) ### What comes next from here? The May 29 paper is open access in *Nature Communications* under the title “Multifactorial sheltering in peristromal niches shapes in vivo responses of lung cancers to targeted therapies.” Nature lists Bina Desai, Tatiana Miti and Andriy Marusyk among the authors. The next step described across the paper summary and related Moffitt materials is clinical translation of combination strategies that target both cancer-cell programs and stromal protection in residual disease. (aacrjournals.org) (nature.com)